Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of autoimmune, oncology and ophthalmic diseases. We think the company's R&amp;D is the top notch among Hong Kong listed biotech companies. It has two near commercialization products, RC18 and RC48.RC18 (BLyS/APRIL target) has an innovative design and has demonstrated a superior efficacy for SLE which has big unmet demand. RC48 (HER2 ADC) is the first domestically developed ADC that has entered the clinical trial stage. It also has a differentiated indication targeting HER2 low-expressing patients, compared to competing drug candidates. Thanks to its ADC platform and bispecific platform, the company has interesting and differentiated pipeline products entering clinical trials.The company has a strong management team and backing from reputable investors. We foresee strong demand for the deal.

RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of autoimmune, oncology and ophthalmic diseases. We think the company's R&amp;D is the top notch among Hong Kong listed biotech companies. It has two near commercialization products, RC18 and RC48.RC18 (BLyS/APRIL target) has an innovative design and has demonstrated a superior efficacy for SLE which has big unmet demand. RC48 (HER2 ADC) is the first domestically developed ADC that has entered the clinical trial stage. It also has a differentiated indication targeting HER2 low-expressing patients, compared to competing drug candidates. Thanks to its ADC platform and bispecific platform, the company has interesting and differentiated pipeline products entering clinical trials.The company has a strong management team and backing from reputable investors. We foresee strong demand for the deal.

RemeGen (荣昌生物) Pre-IPO: 최고의 R&amp;D 역량과 강력한 팀

Remegen

RemeGen (荣昌生物) Pre-IPO: 최고의 R&D 역량과 강력한 팀

Remegen

RemeGen (荣昌生物) Pre-IPO: 최고의 R&amp;D 역량과 강력한 팀

RemeGen (荣昌生物) Pre-IPO: 최고의 R&D 역량과 강력한 팀